Please Wait
Applying Filters...
menu
    • menu
    FDA approvals drop 8% in 2025, with fewer blockbusters; Brinsupri, Rhapsido make it to first-in-class list

    Data Compilation
    #PharmaFlow

    Pipeline Prospector February 2026 highlights: Gilead buys Arcellx for US$ 7.8 bn; FDA okays Vanda’s psychotic pill

    Stock Recap
    #PipelineProspector

    Menu

    Acyclovir (USP)

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    DRUG PRODUCT COMPOSITIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    REF. STANDARDS & IMPURITIES

    ANALYTICAL

    PharmaCompass
    $ API Ref.Price (USD/KG) : 202Xls download

    Filters

    clear-filterReset all filters
    ListList of Suppliers
    refreshReset Filter
    refresh Reset Filter
    Price Info Price Info
    product-page Product Main Page

    Log in to download the data

    Last Updated on PharmaCompass Virtual Booth Country Name of the Firm Written Confirmation No. Product Name Issue Date Valid Till Address of the Firm
    04/06/2025 Apex Healthcare Limited
    India
    		 M/s Apex Healthcare limited WC-0409 Aciclovir BP/EP/USP 2024-03-01 2026-12-31 4710, 4711, 4707-A/8, 4707-A/9, GIDC, Industrial Estate, Ankleshwar, Dist.Bharuch-393002, Gujarat, India
    06/03/2026 Vital Laboratories Private Limited
    India
    		 M/s. Vital Laboratories Limited (Plant -l) WC-0303 Aciclovir EP/BP/USP 2025-05-27 2028-05-20 Plot No. -1416 to 1421, 1507 / 1 & 2 1601, Phase -III, G.I.D.C., Estate, Vapi, Dist. -Valsad -396195, Gujarat, India
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.